vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and TECHPRECISION CORP (TPCS). Click either name above to swap in a different company.
Coherus Oncology, Inc. is the larger business by last-quarter revenue ($12.7M vs $7.1M, roughly 1.8× TECHPRECISION CORP). TECHPRECISION CORP runs the higher net margin — -20.8% vs -295.3%, a 274.5% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs -6.9%). Over the past eight quarters, TECHPRECISION CORP's revenue compounded faster (-9.2% CAGR vs -47.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.
CHRS vs TPCS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $7.1M |
| Net Profit | $-37.6M | $-1.5M |
| Gross Margin | 68.3% | 5.4% |
| Operating Margin | -359.9% | -19.1% |
| Net Margin | -295.3% | -20.8% |
| Revenue YoY | 64.9% | -6.9% |
| Net Profit YoY | 25.7% | -84.4% |
| EPS (diluted) | $-0.34 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | $7.1M | ||
| Q3 25 | $11.6M | $9.1M | ||
| Q2 25 | $10.3M | $7.4M | ||
| Q1 25 | — | $9.5M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | $10.3M | $8.0M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | $-37.6M | $-1.5M | ||
| Q3 25 | $-35.5M | $825.0K | ||
| Q2 25 | $297.8M | $-597.0K | ||
| Q1 25 | — | $112.0K | ||
| Q4 24 | — | $-799.0K | ||
| Q3 24 | — | $-601.0K | ||
| Q2 24 | $-12.9M | $-1.5M | ||
| Q1 24 | — | $-5.1M |
| Q4 25 | 68.3% | 5.4% | ||
| Q3 25 | 67.8% | 27.1% | ||
| Q2 25 | 66.9% | 14.0% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | 82.4% | 3.0% | ||
| Q1 24 | — | 14.3% |
| Q4 25 | -359.9% | -19.1% | ||
| Q3 25 | -383.1% | 10.4% | ||
| Q2 25 | -443.6% | -6.3% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -9.1% | ||
| Q3 24 | — | -5.5% | ||
| Q2 24 | -384.9% | -16.8% | ||
| Q1 24 | — | -28.6% |
| Q4 25 | -295.3% | -20.8% | ||
| Q3 25 | -307.1% | 9.1% | ||
| Q2 25 | 2903.9% | -8.1% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | -10.5% | ||
| Q3 24 | — | -6.7% | ||
| Q2 24 | -125.5% | -18.3% | ||
| Q1 24 | — | -59.5% |
| Q4 25 | $-0.34 | $-0.15 | ||
| Q3 25 | $-0.31 | $0.08 | ||
| Q2 25 | $2.57 | $-0.06 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | $-0.11 | $-0.16 | ||
| Q1 24 | — | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $50.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $8.0M |
| Total Assets | $258.3M | $32.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | $50.0K | ||
| Q3 25 | $191.7M | $220.0K | ||
| Q2 25 | $237.6M | $143.0K | ||
| Q1 25 | — | $195.0K | ||
| Q4 24 | — | $165.0K | ||
| Q3 24 | — | $132.0K | ||
| Q2 24 | $159.2M | $44.8K | ||
| Q1 24 | — | $138.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $3.0K | ||
| Q4 24 | — | $19.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $61.0M | $8.0M | ||
| Q3 25 | $87.8M | $9.1M | ||
| Q2 25 | $119.8M | $8.2M | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $8.1M | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | $-84.1M | $7.9M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | $258.3M | $32.8M | ||
| Q3 25 | $516.5M | $33.8M | ||
| Q2 25 | $439.5M | $32.1M | ||
| Q1 25 | — | $33.5M | ||
| Q4 24 | — | $32.2M | ||
| Q3 24 | — | $35.0M | ||
| Q2 24 | $674.9M | $35.7M | ||
| Q1 24 | — | $34.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $183.0K |
| Free Cash FlowOCF − Capex | — | $-827.0K |
| FCF MarginFCF / Revenue | — | -11.7% |
| Capex IntensityCapex / Revenue | — | 14.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | $183.0K | ||
| Q3 25 | $-46.3M | $-1.1M | ||
| Q2 25 | $-46.6M | $646.0K | ||
| Q1 25 | — | $396.0K | ||
| Q4 24 | — | $-570.0K | ||
| Q3 24 | — | $-532.0K | ||
| Q2 24 | $59.7M | $107.0K | ||
| Q1 24 | — | $-452.0K |
| Q4 25 | — | $-827.0K | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-604.0K | ||
| Q1 25 | — | $-930.0K | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-94.0K | ||
| Q1 24 | — | $-900.0K |
| Q4 25 | — | -11.7% | ||
| Q3 25 | — | -22.9% | ||
| Q2 25 | — | -8.2% | ||
| Q1 25 | — | -9.8% | ||
| Q4 24 | — | -22.9% | ||
| Q3 24 | — | -21.8% | ||
| Q2 24 | — | -1.2% | ||
| Q1 24 | — | -10.5% |
| Q4 25 | — | 14.2% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | 16.9% | ||
| Q1 25 | — | 14.0% | ||
| Q4 24 | — | 15.4% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.31× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | 3.54× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
